Cannabinoid receptor subtype influence on neuritogenesis in human SH-SY5Y cells
Copyright © 2020 Elsevier Inc. All rights reserved..
Human SH-SY5Y neuroblastoma cells stably expressing exogenous CB1 (CB1XS) or CB2 (CB2XS) receptors were developed to investigate endocannabinoid signaling in the extension of neuronal projections. Expression of cannabinoid receptors did not alter proliferation rate, viability, or apoptosis relative to parental SH-SY5Y. Transcripts for endogenous cannabinoid system enzymes (diacylglycerol lipase, monoacylglycerol lipase, α/β-hydrolase domain containing proteins 6 and 12, N-acyl phosphatidylethanolamine-phospholipase D, and fatty acid amide hydrolase) were not altered by CB1 or CB2 expression. Endocannabinoid ligands 2-arachidonoylglycerol (2-AG) and anandamide were quantitated in SH-SY5Y cells, and diacylglycerol lipase inhibitor tetrahydrolipstatin decreased 2-AG abundance by 90% but did not alter anandamide abundance. M3 muscarinic agonist oxotremorine M, and inhibitors of monoacylglycerol lipase and α/β hydrolase domain containing proteins 6 &12 increased 2-AG abundance. CB1 receptor expression increased lengths of short (<30 μm) and long (>30 μm) projections, and this effect was significantly reduced by tetrahydrolipstatin, indicative of stimulation by endogenously produced 2-AG. Pertussis toxin, Gβγ inhibitor gallein, and β-arrestin inhibitor barbadin did not significantly alter long projection length in CB1XS, but significantly reduced short projections, with gallein having the greatest inhibition. The rho kinase inhibitor Y27632 increased CB1 receptor-mediated long projection extension, indicative of actin cytoskeleton involvement. CB1 receptor expression increased GAP43 and ST8SIA2 mRNA and decreased ITGA1 mRNA, whereas CB2 receptor expression increased NCAM and SYT mRNA. We propose that basal endogenous production of 2-AG provides autocrine stimulation of CB1 receptor signaling through Gi/o, Gβγ, and β-arrestin mechanisms to promote neuritogenesis, and rho kinase influences process extension.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:109 |
|---|---|
| Enthalten in: |
Molecular and cellular neurosciences - 109(2020) vom: 15. Dez., Seite 103566 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lyons, Erica L [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 15.10.2021 Date Revised 03.12.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.mcn.2020.103566 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM31619025X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM31619025X | ||
| 003 | DE-627 | ||
| 005 | 20231225160539.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.mcn.2020.103566 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1053.xml |
| 035 | |a (DE-627)NLM31619025X | ||
| 035 | |a (NLM)33049367 | ||
| 035 | |a (PII)S1044-7431(20)30189-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lyons, Erica L |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cannabinoid receptor subtype influence on neuritogenesis in human SH-SY5Y cells |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.10.2021 | ||
| 500 | |a Date Revised 03.12.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier Inc. All rights reserved. | ||
| 520 | |a Human SH-SY5Y neuroblastoma cells stably expressing exogenous CB1 (CB1XS) or CB2 (CB2XS) receptors were developed to investigate endocannabinoid signaling in the extension of neuronal projections. Expression of cannabinoid receptors did not alter proliferation rate, viability, or apoptosis relative to parental SH-SY5Y. Transcripts for endogenous cannabinoid system enzymes (diacylglycerol lipase, monoacylglycerol lipase, α/β-hydrolase domain containing proteins 6 and 12, N-acyl phosphatidylethanolamine-phospholipase D, and fatty acid amide hydrolase) were not altered by CB1 or CB2 expression. Endocannabinoid ligands 2-arachidonoylglycerol (2-AG) and anandamide were quantitated in SH-SY5Y cells, and diacylglycerol lipase inhibitor tetrahydrolipstatin decreased 2-AG abundance by 90% but did not alter anandamide abundance. M3 muscarinic agonist oxotremorine M, and inhibitors of monoacylglycerol lipase and α/β hydrolase domain containing proteins 6 &12 increased 2-AG abundance. CB1 receptor expression increased lengths of short (<30 μm) and long (>30 μm) projections, and this effect was significantly reduced by tetrahydrolipstatin, indicative of stimulation by endogenously produced 2-AG. Pertussis toxin, Gβγ inhibitor gallein, and β-arrestin inhibitor barbadin did not significantly alter long projection length in CB1XS, but significantly reduced short projections, with gallein having the greatest inhibition. The rho kinase inhibitor Y27632 increased CB1 receptor-mediated long projection extension, indicative of actin cytoskeleton involvement. CB1 receptor expression increased GAP43 and ST8SIA2 mRNA and decreased ITGA1 mRNA, whereas CB2 receptor expression increased NCAM and SYT mRNA. We propose that basal endogenous production of 2-AG provides autocrine stimulation of CB1 receptor signaling through Gi/o, Gβγ, and β-arrestin mechanisms to promote neuritogenesis, and rho kinase influences process extension | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Apoptosis | |
| 650 | 4 | |a Endocannabinoid | |
| 650 | 4 | |a Neurite projections | |
| 650 | 4 | |a Neuroblastoma | |
| 650 | 4 | |a Proliferation | |
| 650 | 7 | |a Amides |2 NLM | |
| 650 | 7 | |a Arachidonic Acids |2 NLM | |
| 650 | 7 | |a CNR2 protein, human |2 NLM | |
| 650 | 7 | |a Endocannabinoids |2 NLM | |
| 650 | 7 | |a Glycerides |2 NLM | |
| 650 | 7 | |a Neoplasm Proteins |2 NLM | |
| 650 | 7 | |a Nerve Tissue Proteins |2 NLM | |
| 650 | 7 | |a Polyunsaturated Alkamides |2 NLM | |
| 650 | 7 | |a Pyridines |2 NLM | |
| 650 | 7 | |a Pyrimidines |2 NLM | |
| 650 | 7 | |a RNA, Messenger |2 NLM | |
| 650 | 7 | |a Receptor, Cannabinoid, CB1 |2 NLM | |
| 650 | 7 | |a Receptor, Cannabinoid, CB2 |2 NLM | |
| 650 | 7 | |a Recombinant Proteins |2 NLM | |
| 650 | 7 | |a Xanthenes |2 NLM | |
| 650 | 7 | |a barbadin |2 NLM | |
| 650 | 7 | |a Y 27632 |2 NLM | |
| 650 | 7 | |a 138381-45-0 |2 NLM | |
| 650 | 7 | |a Oxotremorine |2 NLM | |
| 650 | 7 | |a 5RY0UWH1JL |2 NLM | |
| 650 | 7 | |a glyceryl 2-arachidonate |2 NLM | |
| 650 | 7 | |a 8D239QDW64 |2 NLM | |
| 650 | 7 | |a gallein |2 NLM | |
| 650 | 7 | |a 8L0084U2QR |2 NLM | |
| 650 | 7 | |a Orlistat |2 NLM | |
| 650 | 7 | |a 95M8R751W8 |2 NLM | |
| 650 | 7 | |a Pertussis Toxin |2 NLM | |
| 650 | 7 | |a EC 2.4.2.31 |2 NLM | |
| 650 | 7 | |a Lipoprotein Lipase |2 NLM | |
| 650 | 7 | |a EC 3.1.1.34 |2 NLM | |
| 650 | 7 | |a anandamide |2 NLM | |
| 650 | 7 | |a UR5G69TJKH |2 NLM | |
| 700 | 1 | |a Leone-Kabler, Sandra |e verfasserin |4 aut | |
| 700 | 1 | |a Kovach, Alexander L |e verfasserin |4 aut | |
| 700 | 1 | |a Thomas, Brian F |e verfasserin |4 aut | |
| 700 | 1 | |a Howlett, Allyn C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molecular and cellular neurosciences |d 1990 |g 109(2020) vom: 15. Dez., Seite 103566 |w (DE-627)NLM074732943 |x 1095-9327 |7 nnns |
| 773 | 1 | 8 | |g volume:109 |g year:2020 |g day:15 |g month:12 |g pages:103566 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.mcn.2020.103566 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 109 |j 2020 |b 15 |c 12 |h 103566 | ||